Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Chris H. Takimoto, Kira Glover, Xiaoke Huang, Steven A. Hayes, Lilia Gallot, Mary Quinn, Borko D. Jovanovic, Alla Shapiro, Leticia Hernandez, Andrew Goetz, Victor Llorens, Ronald Lieberman, James A. Crowell, Brett A. Poisson, Raymond Bergan

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Preclinical studies suggest that the isoflavone genistein may have prostate cancer chemopreventive activity. Genistein has been shown to alter cellular levels of protein-tyrosine phosphorylation and is present at high levels in soy. This study was designed to measure the pharmacokinetic parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and PTI G-4660 (which contain 43% and 90% genistein, respectively), in human subjects with cancer, to evaluate toxicity and obtain pilot data on in vivo effects on protein-tyrosine phosphorylation. Cohorts of four patients were given single doses of each preparation; each dose was separated by 1 week. Sequential cohorts received genistein at 2, 4, or 8 mg/kg orally. Pharmacokinetic sampling was performed after each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral blood mononuclear cells. One of 13 patients treated developed a treatment-related rash. No other toxicities were observed. Maximal plasma concentrations (C max) ranged between 4.3 and 16.3 μM for total genistein and 0.066 and 0.17 μM for free genistein. For PTI G-2535 and PTI G-4660, half-life was 15.03 and 22.41 h, respectively, and volume of distribution was 189.9 and 653.8 liters, respectively, and there was a trend toward higher area under the concentration curve for PTI G-2535 (P = 0.07 at the 8 mg/kg dose). Treatment-related increases in tyrosine phosphorylation were observed in peripheral blood mononuclear cells. Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro.

Original languageEnglish (US)
Pages (from-to)1213-1221
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume12
Issue number11 II
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Isoflavones
Genistein
Pharmacokinetics
Tyrosine
Phosphorylation
Neoplasms
Blood Cells
Proteins
Exanthema
Area Under Curve
Oral Administration
Half-Life
Prostatic Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer. / Takimoto, Chris H.; Glover, Kira; Huang, Xiaoke; Hayes, Steven A.; Gallot, Lilia; Quinn, Mary; Jovanovic, Borko D.; Shapiro, Alla; Hernandez, Leticia; Goetz, Andrew; Llorens, Victor; Lieberman, Ronald; Crowell, James A.; Poisson, Brett A.; Bergan, Raymond.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 12, No. 11 II, 11.2003, p. 1213-1221.

Research output: Contribution to journalArticle

Takimoto, CH, Glover, K, Huang, X, Hayes, SA, Gallot, L, Quinn, M, Jovanovic, BD, Shapiro, A, Hernandez, L, Goetz, A, Llorens, V, Lieberman, R, Crowell, JA, Poisson, BA & Bergan, R 2003, 'Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 11 II, pp. 1213-1221.
Takimoto, Chris H. ; Glover, Kira ; Huang, Xiaoke ; Hayes, Steven A. ; Gallot, Lilia ; Quinn, Mary ; Jovanovic, Borko D. ; Shapiro, Alla ; Hernandez, Leticia ; Goetz, Andrew ; Llorens, Victor ; Lieberman, Ronald ; Crowell, James A. ; Poisson, Brett A. ; Bergan, Raymond. / Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2003 ; Vol. 12, No. 11 II. pp. 1213-1221.
@article{b4601c7933894b6abe46fdda77b82904,
title = "Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer",
abstract = "Preclinical studies suggest that the isoflavone genistein may have prostate cancer chemopreventive activity. Genistein has been shown to alter cellular levels of protein-tyrosine phosphorylation and is present at high levels in soy. This study was designed to measure the pharmacokinetic parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and PTI G-4660 (which contain 43{\%} and 90{\%} genistein, respectively), in human subjects with cancer, to evaluate toxicity and obtain pilot data on in vivo effects on protein-tyrosine phosphorylation. Cohorts of four patients were given single doses of each preparation; each dose was separated by 1 week. Sequential cohorts received genistein at 2, 4, or 8 mg/kg orally. Pharmacokinetic sampling was performed after each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral blood mononuclear cells. One of 13 patients treated developed a treatment-related rash. No other toxicities were observed. Maximal plasma concentrations (C max) ranged between 4.3 and 16.3 μM for total genistein and 0.066 and 0.17 μM for free genistein. For PTI G-2535 and PTI G-4660, half-life was 15.03 and 22.41 h, respectively, and volume of distribution was 189.9 and 653.8 liters, respectively, and there was a trend toward higher area under the concentration curve for PTI G-2535 (P = 0.07 at the 8 mg/kg dose). Treatment-related increases in tyrosine phosphorylation were observed in peripheral blood mononuclear cells. Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro.",
author = "Takimoto, {Chris H.} and Kira Glover and Xiaoke Huang and Hayes, {Steven A.} and Lilia Gallot and Mary Quinn and Jovanovic, {Borko D.} and Alla Shapiro and Leticia Hernandez and Andrew Goetz and Victor Llorens and Ronald Lieberman and Crowell, {James A.} and Poisson, {Brett A.} and Raymond Bergan",
year = "2003",
month = "11",
language = "English (US)",
volume = "12",
pages = "1213--1221",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11 II",

}

TY - JOUR

T1 - Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

AU - Takimoto, Chris H.

AU - Glover, Kira

AU - Huang, Xiaoke

AU - Hayes, Steven A.

AU - Gallot, Lilia

AU - Quinn, Mary

AU - Jovanovic, Borko D.

AU - Shapiro, Alla

AU - Hernandez, Leticia

AU - Goetz, Andrew

AU - Llorens, Victor

AU - Lieberman, Ronald

AU - Crowell, James A.

AU - Poisson, Brett A.

AU - Bergan, Raymond

PY - 2003/11

Y1 - 2003/11

N2 - Preclinical studies suggest that the isoflavone genistein may have prostate cancer chemopreventive activity. Genistein has been shown to alter cellular levels of protein-tyrosine phosphorylation and is present at high levels in soy. This study was designed to measure the pharmacokinetic parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and PTI G-4660 (which contain 43% and 90% genistein, respectively), in human subjects with cancer, to evaluate toxicity and obtain pilot data on in vivo effects on protein-tyrosine phosphorylation. Cohorts of four patients were given single doses of each preparation; each dose was separated by 1 week. Sequential cohorts received genistein at 2, 4, or 8 mg/kg orally. Pharmacokinetic sampling was performed after each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral blood mononuclear cells. One of 13 patients treated developed a treatment-related rash. No other toxicities were observed. Maximal plasma concentrations (C max) ranged between 4.3 and 16.3 μM for total genistein and 0.066 and 0.17 μM for free genistein. For PTI G-2535 and PTI G-4660, half-life was 15.03 and 22.41 h, respectively, and volume of distribution was 189.9 and 653.8 liters, respectively, and there was a trend toward higher area under the concentration curve for PTI G-2535 (P = 0.07 at the 8 mg/kg dose). Treatment-related increases in tyrosine phosphorylation were observed in peripheral blood mononuclear cells. Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro.

AB - Preclinical studies suggest that the isoflavone genistein may have prostate cancer chemopreventive activity. Genistein has been shown to alter cellular levels of protein-tyrosine phosphorylation and is present at high levels in soy. This study was designed to measure the pharmacokinetic parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and PTI G-4660 (which contain 43% and 90% genistein, respectively), in human subjects with cancer, to evaluate toxicity and obtain pilot data on in vivo effects on protein-tyrosine phosphorylation. Cohorts of four patients were given single doses of each preparation; each dose was separated by 1 week. Sequential cohorts received genistein at 2, 4, or 8 mg/kg orally. Pharmacokinetic sampling was performed after each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral blood mononuclear cells. One of 13 patients treated developed a treatment-related rash. No other toxicities were observed. Maximal plasma concentrations (C max) ranged between 4.3 and 16.3 μM for total genistein and 0.066 and 0.17 μM for free genistein. For PTI G-2535 and PTI G-4660, half-life was 15.03 and 22.41 h, respectively, and volume of distribution was 189.9 and 653.8 liters, respectively, and there was a trend toward higher area under the concentration curve for PTI G-2535 (P = 0.07 at the 8 mg/kg dose). Treatment-related increases in tyrosine phosphorylation were observed in peripheral blood mononuclear cells. Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro.

UR - http://www.scopus.com/inward/record.url?scp=10744226314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226314&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1213

EP - 1221

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11 II

ER -